CANY
DNA icon

Caxton Associates (New York)’s Ginkgo Bioworks DNA Stock Holding History

Caxton Associates (New York)’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-59,415
Closed -$484K – 538
2024
Q3 		$484K Buy
+59,415
New +$595K 0.02% 366
2024
Q2 		– Sell
-9,435
Closed -$438K – 506
2024
Q1 		$438K Buy
+9,435
New +$488K 0.02% 341

Other funds holding DNA

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Caxton Associates (New York)'s DNA Position: Q4 2024 in Review

Caxton Associates (New York) sold out of Ginkgo Bioworks (DNA) in Q4 2024, closing a stake of 59,415 shares — an estimated $484K sold.

Caxton Associates (New York) first reported a position in DNA in Q1 2024 and held it in 2 quarters. The position peaked at $484K in Q3 2024. 165 funds tracked by Wall St. Rank hold DNA as of Q4 2024.

  • Caxton Associates (New York) reported no remaining Ginkgo Bioworks position as of Q4 2024 after selling out during the quarter.
  • Caxton Associates (New York) sold 59,415 Ginkgo Bioworks shares in Q4 2024, an estimated $484K.
  • Caxton Associates (New York) first reported a position in Ginkgo Bioworks in Q1 2024 and held it in 2 quarters.
  • Caxton Associates (New York)'s Ginkgo Bioworks position peaked at $484K in Q3 2024.
  • 165 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q4 2024.

Based on Caxton Associates (New York)'s 13F filing for Q4 2024, filed 14 Feb 2025.